Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients
ICIs provide meaningful benefits to immunosuppressed MCC patients, though their response rates are lower, and progression risk is higher compared with immunocompetent patients.
Authors
- Allison J Remington
- Tomoko Akaike (ORCID: https://orcid.org/0000-0003-4525-6408)
- Kristina Lachance (ORCID: https://orcid.org/0000-0002-2697-268X)
- Song Y. Park (ORCID: https://orcid.org/0000-0003-4366-1821)
- Lauren Zawacki
- A. Menon
- Lisa Tachiki (ORCID: https://orcid.org/0000-0001-8057-8029)
- Emily Gong
- Daniel S. Hippe (ORCID: https://orcid.org/0000-0003-2427-4404)
- Paul Nghiem (ORCID: https://orcid.org/0000-0003-2784-963X)
- Xinyi Fan
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- BMJ Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/bmjonc-2024-000654
- Citations
- 5
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- University of Washington
- Incyte
- Seagen
- National Cancer Institute